

## Sanofi invests €400 M in first-of-its kind vaccines mRNA Center of Excellence

29 June 2021 | News

**Expected minimum of six clinical candidates by 2025**



Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence.

The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l'Etoile, Lyon (France).

*“During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. However, key areas of innovation such as thermostability and tolerability improvements will be critical to unlock the applications of mRNA in routine vaccination against a broader set of infectious diseases and across all ages. The Sanofi mRNA vaccines Center of Excellence aims to lead the field in this next chapter of vaccine innovation,”* said Jean-Francois Toussaint, Global Head of Research and Development, Sanofi Pasteur.

The Center of Excellence will enable acceleration of the vaccines mRNA portfolio developed through the Translate Bio collaboration established in 2018 and expanded in 2020.